Seeking AlphaCodex · 实盘不做把握 6/10
北京时间·🕒 发布 08-03 19:07:48时区推断·⟳ 抓取 08-03 19:08:01·⚡ 决策 08-04 09:16:00 +14h07m·84.4 天前
Ocular Therapeutix二季度EPS和收入小幅好于预期但收入基本持平
Q2 GAAP EPS为-0.35美元，好于预期0.04美元；收入1348万美元，好于预期28万美元。
📄 原文Seeking Alpha↗ 原文
Ocular Therapeutix GAAP EPS of -$0.35 beats by $0.04, revenue of $13.48M beats by $0.28M
- Ocular Therapeutix press release (OCUL): Q2 GAAP EPS of -$0.35 beats by $0.04. - Revenue of $13.48M (+0.1% Y/Y) beats…
不做 Ocular Therapeutix（OCUL.US）
财报仅小幅超预期且收入同比基本持平，盘前披露后已交易一日，剩余短线edge不足，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 medium · price-in 风险 high ↗
消息传播链
- 报道Ocular二季度EPS小幅超预期、收入1348万美元小幅超预期且现金可支撑至2028年。市场反应:OCUL.US当日收8.385美元，较前收8.15美元上涨2.88%。
关键理由
- Q2 GAAP EPS为-0.35美元，好于预期0.04美元；收入1348万美元，好于预期28万美元。
- 总净收入约1350万美元，同比基本持平，DEXTENZA产品收入仅同比增加10万美元或0.6%，不是强增长催化。
- 现金及等价物5.986亿美元，管理层称可支持运营至2028年，偏正面但已属财报常规披露。
主要风险
- 收入超预期幅度仅约28万美元，产品收入几乎持平，难以支撑隔日继续追多。
工具调用 · 历史记录,结果未知(1 种)
- stock_quote · 结果未知
原文全文
展开原文 · 846 字
- Ocular Therapeutix press release (OCUL): Q2 GAAP EPS of -$0.35 beats by $0.04.
- Revenue of $13.48M (+0.1% Y/Y) beats by $0.28M.
- Total net revenue was $13.5 million for the second quarter of 2026, flat as compared to the comparable quarter of 2025. Total net revenue includes both gross DEXTENZA product revenue, net of discounts, rebates, and returns, which increased $0.1 million or 0.6% over Q2 2025, and collaboration revenue, which was $0.0 million in Q2 2026 versus $0.1 million in Q2 2025.
- Total cash and cash equivalents were $598.6 million as of June 30, 2026. Based on current plans and related estimates of anticipated cash inflows from DEXTENZA®, the Company believes that its current cash balance is sufficient to support its planned operating expenses, debt service obligations, and capital expenditure requirements into 2028.
- Revenue of $13.48M (+0.1% Y/Y) beats by $0.28M.
- Total net revenue was $13.5 million for the second quarter of 2026, flat as compared to the comparable quarter of 2025. Total net revenue includes both gross DEXTENZA product revenue, net of discounts, rebates, and returns, which increased $0.1 million or 0.6% over Q2 2025, and collaboration revenue, which was $0.0 million in Q2 2026 versus $0.1 million in Q2 2025.
- Total cash and cash equivalents were $598.6 million as of June 30, 2026. Based on current plans and related estimates of anticipated cash inflows from DEXTENZA®, the Company believes that its current cash balance is sufficient to support its planned operating expenses, debt service obligations, and capital expenditure requirements into 2028.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。